Funded Projects
Project # | Project Title | Research Focus Area | Research Program | Administering IC(s) | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
2R44DA043325-02
Show Summary |
SENSITIVE AND PORTABLE PHYSICIAN OFFICE-BASED URINE ANALYZER TO TACKLE PRESCRIPTION DRUG ABUSE | Cross-Cutting Research | Small Business Programs | NIDA | BreviTest Technologies, LLC | Heffernan, Michael John | HOUSTON, TX | 2019 |
FOA Title: PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
FOA Number: PA-18-574 Summary: Current drug-screening immunoassays use benchtop analyzers that require experienced personnel, time, and a laboratory setup. Physicians without access to in-house testing have to send out patient samples for screening, resulting in unacceptable delays in the treatment of patients who are potentially suffering from chronic pain. This project, a partnership with BreviTest Technologies, LLC, aims to develop a low-cost, point-of-care (POC) urine drug testing (UDT) device to detect opioids. The goal is for a portable platform to deliver quantitative performance similar to a standard laboratory test for opioids within a 10-minute run time. If successful, this will provide a technology capable of performing rapid quantifications of urine drug levels in a physician’s office, providing an invaluable tool to render more effective pain management dosing to patients, thus paving the way toward lower toxicity and a better quality of life. |